Buy Rating Affirmed for VYNE Therapeutics Amidst Favorable IND Clearance and Promising VYN202 Development

by | May 6, 2024 | FEATURED, HEADLINE, Stocks

 LifeSci Capital analyst Rami Katkhuda has maintained their bullish stance on VYNE stock, giving a Buy rating today.Rami Katkhuda has given his Buy … 

 

Read More 

FEATURED

Why Have Stocks Soared Since The April Lows?

 Stocks and bonds rose last week, continuing the robust rally since mid-April. The 1.6% increase in the S&P 500 took the index to a new all-time high territory last week. The Magnificent 7, consisting of Microsoft Microsoft(MSFT), Meta Platforms Meta...

read more